Savara (SVRA) Non Operating Income (2017 - 2026)
Savara (SVRA) posted quarterly Non Operating Income of $1.1 million for Q1 2026, down 29.44% year-over-year from $1.5 million in Q1 2025, and down 11.55% quarter-over-quarter from $1.2 million in Q4 2025.
Savara (SVRA) Non Operating Income (2017 - 2026) Analysis & Trends
Savara (SVRA) has reported Non Operating Income for 10 consecutive years, with $1.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non Operating Income fell 29.44% year-over-year to $1.1 million; the TTM figure through Mar 2026 stood at $3.7 million (down 43.72% YoY), while the FY2025 annual figure was $4.2 million, down 35.64% from the prior year.
- Non Operating Income slipped to $1.1 million in Q1 2026 per SVRA's latest filing, from $1.2 million in the prior quarter.
- Across five years, Non Operating Income topped out at $2.1 million in Q3 2024 and bottomed at -$570000.0 in Q1 2022.
- Historically, Non Operating Income has averaged $943235.3 across 5 years, with a median of $1.1 million in 2026.
- Annual changes were most pronounced in 2023 — Non Operating Income soared 850.0% — and 2025, when it tumbled 74.26%.
- Savara's Non Operating Income stood at $614000.0 in 2022, then jumped by 147.39% to $1.5 million in 2023, then climbed by 25.94% to $1.9 million in 2024, then tumbled by 37.53% to $1.2 million in 2025, then declined by 11.55% to $1.1 million in 2026.
- Business Quant data shows SVRA's Non Operating Income at $1.1 million in Q1 2026, $1.2 million in Q4 2025, and $548000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Savara | 1.11 Bn | 1.11 Bn | - | 829,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 829,000.00 |
| Mar 31, 2026 | 1.06 Mn |
| Dec 31, 2025 | 1.20 Mn |
| Sep 30, 2025 | 548,000.00 |
| Jun 30, 2025 | 921,000.00 |
| Mar 31, 2025 | 1.50 Mn |
| Dec 31, 2024 | 1.91 Mn |
| Sep 30, 2024 | 2.13 Mn |
| Jun 30, 2024 | 1.07 Mn |
| Mar 31, 2024 | 1.35 Mn |
| Dec 31, 2023 | 1.52 Mn |
| Sep 30, 2023 | 1.44 Mn |
| Jun 30, 2023 | 709,000.00 |
| Mar 31, 2023 | 765,000.00 |
| Dec 31, 2022 | 614,000.00 |
| Sep 30, 2022 | 152,000.00 |
| Jun 30, 2022 | -284,000.00 |
| Mar 31, 2022 | -570,000.00 |
| Dec 31, 2021 | -565,000.00 |
| Sep 30, 2021 | -566,000.00 |